Released Mar 29, 2012, after the close
10-K filed Mar 30, 2012, 90 days after period end · 0001019687-12-001146
Q4 2011 · 10-K
Revenue$6.10M$6.10M no prior Q4 2010 on file+4.0% vs Q3 2011
Net Income-$1.04M-$1.04M no prior Q4 2010 on fileN/M vs Q3 2011
EPS Diluted-$0.02-$0.02 no prior Q4 2010 on fileN/M vs Q3 2011
Operating Income-$908,000—
Operating Cash Flowderived-$127,000N/M
Free Cash Flowderived-$419,000N/M
Margins · derived
Operating margin-14.9%
Net margin-17.0%
What the release said
The release
Same quarter
| Metric | Q4 2011 | Q4 2010dderived from reported figures |
|---|---|---|
| Revenue | $6.10M | — |
| Net Income | -$1.04M | — |
| EPS Diluted | -$0.02 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR